Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications

Apoptosis

Volumn 8, Issue 4, 2003, Pages 337-343

  Chauhan, D ^a   Anderson, K C ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Mitochondria; Multiple myeloma; Protease inhibitor; Protective signaling

Indexed keywords

2 METHOXYESTRADIOL; BORTEZOMIB; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; PROTEASOME INHIBITOR; THALIDOMIDE;

BONE MARROW CANCER; CELL DEATH; CELL GROWTH; CELL SURVIVAL; DISEASE COURSE; DRUG EXPOSURE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MITOCHONDRION; MULTIPLE MYELOMA; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL DEATH; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MITOCHONDRIA; MITOGEN-ACTIVATED PROTEIN KINASES; MULTIPLE MYELOMA; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 0042167462     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024164700094     Document Type: Short Survey

References (55)

1. Anderson KC. Moving disease biology from the lab to the clinic. Cancer 2003; 97: 796-801.
2. Chauhan D, Pandey P, Hideshima T, et al. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem 2000; 275:27845-27850.
3. Chauhan D, Anderson KC. Apoptosis in multiple myeloma: Therapeutic implications. Apoptosis 2001; 6: 47-55.
4. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002;2:927-937.
5. Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF. Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol 2001; 3: 339-345.
6. Sahara S, Aoto M, Eguchi Y, Imamoto N, Yoneda Y, Tsujimoto Y. Acinus is a caspase-3-activated protein required for apoptotic chromatin condensation. Nature 1999; 401: 168-173.
7. Willie AH, Kerr JF, Currie AR. Cell death: The significance of apoptosis. Int Rev Cytol 1980; 68: 251-306.
8. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwanatsu A, Natata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998; 391: 43-50.
9. Chinnaiyan AM, Dixit VM. The cell-death machine. Curr Biol 1996; 6: 555-562.
10. Thornberry NA, Lazebnik Y. Caspases: Enemies within. Science 1998; 281: 1312-1316.
11. Oberhammer FA, Hochegger K, Froschl G, Tiefenbacher R, Pavelka M. Chromatin condensation during apoptosis is accompanied by degradation of lamin A + B, without enhanced activation of cdc2 kinase. J Cell Biol 1994; 126: 827-837.
12. Nguyen M, Millar DG, Yong VW, Korsmeyer SJ, Shore GC. Targeting of Bcl-2 to the mitochondrial outer membrane by a COOH-terminal signal anchor sequence. J Biol Chem 1993; 268: 25265-25268.
13. Newmeyer DD, Farschon DM, Reed JC. Cell-free apoptosis in Xenopus egg extracts: Inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria. Cell 1994; 79: 353-364.
14. Zamzami N, Marchetti P, Castedo M, et al. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med 1995; 182: 367-377.
15. Srinivasula SM, Datta P, Fan XJ, Fernandes-Alnemri T, Huang Z, Alnemri ES. Molecular determinants of the caspase-promoting activity of Smac/DIABLO and its role in the death receptor pathway. J Biol Chem 2000; 275: 36152-36157.
16. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33-42.
17. Chauhan D, Pandey P, Ogata A, et al. Cytochrome-c dependent and independent induction of apoptosis in multiple myeloma cells. J Biol Chem 1997; 272: 29995-29997.
18. Kyriakis JM, Avruch J. Sounding the alarm: Protein kinase cascades activated by stress and inflammation. J Biol Chem 1996; 271: 24313-24316.
19. Derijard B, Hibi M, Wu IH, et al. JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 1994; 76: 1025-1037.
20. Verheij M, Bose R, Lin XH, et al. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 1996; 380: 75-79.
21. Tournier C, Hess P, Yang DD, et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000; 288: 870-874.
22. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000; 6: 513-519.
23. Kharbanda S, Saxena S, Yoshida K, et al. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage. J Biol Chem 2000; 275: 322-327.
24. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science 2001; 292: 727-730.
25. Lei K, Nimnual A, Zong WX, et al. The Bax subfamily of Bcl2-related proteins is essential for apoptotic signal transduction by c-Jun NH(2)-terminal kinase. Mol Cell Biol 2002; 22: 4929-4942.
26. Chauhan D, Pandey P, Ogata A, et al. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene 1997; 15: 837-843.
27. Chauhan D, Hideshima T, Rosen S, Reed JC, Kharbanda S, Anderson KC. Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. J Biol Chem 2001; 276: 24453-24456.
28. Alexanian R, Barlogie B, Dixon D. High dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986; 105: 8-11.
29. Chatterjee M, Honemann D, Lentzsch S, et al. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood 2002;100:3311-3318.
30. Le Gouill S, Pellat-Deccunynck C, Harousseau JL, et al. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia 2002; 16: 1664-1667.
31. Bolick SC, Landowski TH, Boulware D, et al. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia 2003; 17: 451-457.
32. Uchiyama H, Anderson KC. Cellular adhesion molecules. Transfusion Medicine Reviews. 1994; viii: 84-95.
33. Raje N, Anderson KC. Thalidomide: A revival story. N Engl J Med 1999; 341: 1606-1609.
34. Damiano JS, Cress AE, Hazlehurst LA, Shatil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93: 1658-1667.
35. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates IL-6 secretion. Blood 1993; 82:3712-3720.
36. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappaB. Blood 1996; 87: 1104-1112.
37. Hideshima T, Chauhan D, Richardson P, et al. NF-kappaB as a therapeutic target in multiple myeloma. J Biol Chem 2002; 28: 28.
38. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and Ikappa B-alpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003; 101: 1053-1062.
39. Akiyama M, Hideshima T, Hayashi T, et al. Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res 2003; 63: 18-21.
40. Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: Therapeutic applications. Blood 2002; 99: 4079-4086.
41. Kawano MM, Huang N, Tanaka H, et al. Homotypic cell aggregations of human myeloma cells with ICAM-1 and LFA-1 molecules. Br J Haematol 1991; 79: 583-588.
42. Ishikawa H, Tsuyama N, Abroun S, et al. Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6. Blood 2002; 99: 2172-2178.
43. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001; 20: 5991-6000.
44. Qiang YW, Kopantzev E, Rudikoff S. Insulin-like growth factor-I signaling in multiple myeloma: Downstream elements, functional correlates, and pathway cross-talk. Blood 2002; 99: 4138-4146.
45. Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: Therapeutic implications. Oncogene 2002; 21: 5673-5683.
46. Tassone P, Forciniti S, Galea E, et al. Synergistic induction of growth arrest and apoptosis of human myeloma cells by the IL-6 super-antagonist Sant7 and Dexamethasone. Cell Death Differ 2000; 7: 327-328.
47. Hirata T, Shimazaki C, Sumikuma T, et al. Humanized antiinterleukin-6 receptor monoclonal antibody induced apoptosis of fresh and cloned human myeloma cells in vitro. Leuk Res 2003; 27: 343-349.
48. Chauhan D, Auclair D, Robinson EK, et al. Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene 2002; 21: 1346-1358.
49. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99: 14374-14379.
50. Mitsiades N, Mitsiades CS, Richardson PG, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003.
51. Van de Donk NW, Kamphuis MM, van Dijk M, Borst HP, Bloem AC, Lokhorst HM. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. Leukemia 2003; 17: 211-219.
52. Derenne S, Monia B, Dean NM, etal. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002; 100: 194-199.
53. Dai Y, Landowski TH, Rosen ST, Dent P, Grant S. Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and - resistant myeloma cells through an IL-6-independent mechanism. Blood 2002; 100: 3333-3343.
54. Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 2003; 9: 316-326.
55. Vanderkerken K, De Leenheer E, Shipman C, et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 2003;63:287-289.